Theravance Biopharma TBPH Stock
Theravance Biopharma Price Chart
Theravance Biopharma TBPH Financial and Trading Overview
| Theravance Biopharma stock price | 16.93 USD |
| Previous Close | 16.92 USD |
| Open | 16.92 USD |
| Bid | 12.14 USD x 200 |
| Ask | 21.64 USD x 200 |
| Day's Range | 16.91 - 16.95 USD |
| 52 Week Range | 11.3 - 21.03 USD |
| Volume | 2.72M USD |
| Avg. Volume | 637.78K USD |
| Market Cap | 877.45M USD |
| Beta (5Y Monthly) | 0.246 |
| PE Ratio (TTM) | 7.5919285 |
| EPS (TTM) | 2.23 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.67 USD |
TBPH Valuation Measures
| Enterprise Value | 518.63M USD |
| Trailing P/E | 7.5919285 |
| Forward P/E | 21.1625 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.99319 |
| Price/Book (mrq) | 3.001241 |
| Enterprise Value/Revenue | 4.724 |
| Enterprise Value/EBITDA | 78.867 |
Trading Information
Theravance Biopharma Stock Price History
| Beta (5Y Monthly) | 0.246 |
| 52-Week Change | 48.50% |
| S&P500 52-Week Change | 21.71% |
| 52 Week High | 21.03 USD |
| 52 Week Low | 11.3 USD |
| 50-Day Moving Average | 16.75 USD |
| 200-Day Moving Average | 17.12 USD |
TBPH Share Statistics
| Avg. Volume (3 month) | 637.78K USD |
| Avg. Daily Volume (10-Days) | 611.83K USD |
| Shares Outstanding | 51.83M |
| Float | 23.87M |
| Short Ratio | 4.62 |
| % Held by Insiders | 4.68% |
| % Held by Institutions | 99.18% |
| Shares Short | 4.31M |
| Short % of Float | 13.27% |
| Short % of Shares Outstanding | 8.31% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 104.34% |
| Operating Margin (ttm) | -33.053% |
| Gross Margin | 71.04% |
| EBITDA Margin | 5.98% |
Management Effectiveness
| Return on Assets (ttm) | 0.76% |
| Return on Equity (ttm) | 50.17% |
Income Statement
| Revenue (ttm) | 109.78M USD |
| Revenue Per Share (ttm) | 2.17 USD |
| Quarterly Revenue Growth (yoy) | 15.00% |
| Gross Profit (ttm) | 77.98M USD |
| EBITDA | 6.58M USD |
| Net Income Avi to Common (ttm) | 114.54M USD |
| Diluted EPS (ttm) | 2.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 394.67M USD |
| Total Cash Per Share (mrq) | 7.66 USD |
| Total Debt (mrq) | 40.5M USD |
| Total Debt/Equity (mrq) | 13.94 USD |
| Current Ratio (mrq) | 13.143 |
| Book Value Per Share (mrq) | 5.641 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 268.78M USD |
| Levered Free Cash Flow (ttm) | 22.51M USD |
Profile of Theravance Biopharma
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 901 Gateway Boulevard |
| ZIP | 94080 |
| Phone | 650 808 6000 |
| Website | https://www.theravance.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 90 |
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Q&A For Theravance Biopharma Stock
What is a current TBPH stock price?
Theravance Biopharma TBPH stock price today per share is 16.93 USD.
How to purchase Theravance Biopharma stock?
You can buy TBPH shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Theravance Biopharma?
The stock symbol or ticker of Theravance Biopharma is TBPH.
Which industry does the Theravance Biopharma company belong to?
The Theravance Biopharma industry is Biotechnology.
How many shares does Theravance Biopharma have in circulation?
The max supply of Theravance Biopharma shares is 51.83M.
What is Theravance Biopharma Price to Earnings Ratio (PE Ratio)?
Theravance Biopharma PE Ratio is 7.59192850 now.
What was Theravance Biopharma earnings per share over the trailing 12 months (TTM)?
Theravance Biopharma EPS is 2.23 USD over the trailing 12 months.
Which sector does the Theravance Biopharma company belong to?
The Theravance Biopharma sector is Healthcare.
Theravance Biopharma TBPH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26690.62 USD — |
+1.3
|
7.21B USD — | 26478.01 USD — | 26712.62 USD — | — - | 7.21B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2352.21 USD — |
+2.01
|
— — | 2329.02 USD — | 2354.46 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6781.84 USD — |
+1.84
|
— — | 6687.79 USD — | 6788.59 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.16 USD — |
+2.08
|
— — | 1273.79 USD — | 1294.2 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32930.06 USD — |
+1.3
|
— — | 32667.75 USD — | 32957.2 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global BuyBack Achievers
DRBG
US
|
3151.97 USD — |
+0.38
|
— — | 3141.25 USD — | 3155.41 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7401.52 USD — |
+1.84
|
— — | 7298.88 USD — | 7408.88 USD — | — - | — — |
- {{ link.label }} {{link}}
